Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

Similar articles for PubMed (Select 23199645)

1.

Reprint of: Vitamin D receptor activation and prevention of arterial ageing.

Cozzolino M, Stucchi A, Rizzo MA, Soldati L, Cusi D, Ciceri P, Brenna I, Elli F, Gallieni M.

Nutr Metab Cardiovasc Dis. 2013 Dec;23 Suppl 1:S31-6. doi: 10.1016/j.numecd.2012.11.001. Epub 2012 Nov 28.

PMID:
23199645
2.

Vitamin D receptor activation and prevention of arterial ageing.

Cozzolino M, Stucchi A, Rizzo MA, Soldati L, Cusi D, Ciceri P, Brenna I, Elli F, Gallieni M.

Nutr Metab Cardiovasc Dis. 2012 Jul;22(7):547-52. doi: 10.1016/j.numecd.2012.03.010. Epub 2012 May 24. Review.

PMID:
22633189
3.

The impact of paricalcitol on left ventricular hypertrophy.

Cozzolino M, Ronco C.

Contrib Nephrol. 2011;171:161-5. doi: 10.1159/000327170. Epub 2011 May 23. Review.

PMID:
21625106
4.
5.

Restoring the physiology of vitamin D receptor activation and the concept of selectivity.

Cozzolino M, Brenna I, Volpi E, Ciceri P, Mehmeti F, Cusi D.

Contrib Nephrol. 2011;171:151-6. doi: 10.1159/000327166. Epub 2011 May 23. Review.

PMID:
21625104
6.

Vascular calcification in chronic kidney failure: role of vitamin D receptor.

Wu-Wong JR, Melnick J.

Curr Opin Investig Drugs. 2007 Mar;8(3):237-47. Review.

PMID:
17408120
7.
8.

Importance of vitamin D receptor activation in clinical practice.

Cozzolino M, Fallabrino G, Pasho S, Olivi L, Ciceri P, Volpi E, Gallieni M, Brancaccio D.

Contrib Nephrol. 2009;163:213-8. doi: 10.1159/000223801. Epub 2009 Jun 3.

PMID:
19494616
9.

Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies.

Brancaccio D, Bommer J, Coyne D.

Drugs. 2007;67(14):1981-98. Review. Erratum in: Drugs. 2007;67(17):2556.

PMID:
17883283
10.

Vitamin D receptor activation and cardiovascular disease.

Gonzalez-Parra E, Rojas-Rivera J, Tuñón J, Praga M, Ortiz A, Egido J.

Nephrol Dial Transplant. 2012 Dec;27 Suppl 4:iv17-21. doi: 10.1093/ndt/gfs534. Review.

11.

Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.

Cozzolino M, Brancaccio D.

Expert Opin Pharmacother. 2008 Apr;9(6):947-54. doi: 10.1517/14656566.9.6.947. Review.

PMID:
18377338
12.

Bone health and vascular calcification relationships in chronic kidney disease.

Spasovski GB.

Int Urol Nephrol. 2007;39(4):1209-16. Epub 2007 Sep 26. Review.

PMID:
17899431
13.

The vitamin D system: a crosstalk between the heart and kidney.

Cozzolino M, Ketteler M, Zehnder D.

Eur J Heart Fail. 2010 Oct;12(10):1031-41. doi: 10.1093/eurjhf/hfq112. Epub 2010 Jul 6.

PMID:
20605845
14.

Vitamin D treatment in chronic kidney disease.

Andress DL.

Semin Dial. 2005 Jul-Aug;18(4):315-21. Review.

PMID:
16076355
15.

Vascular calcification and arterial stiffness in chronic kidney disease: implications and management.

Toussaint ND, Kerr PG.

Nephrology (Carlton). 2007 Oct;12(5):500-9. Review.

PMID:
17803475
16.

Potential for vitamin D receptor agonists in the treatment of cardiovascular disease.

Wu-Wong JR.

Br J Pharmacol. 2009 Sep;158(2):395-412. doi: 10.1111/j.1476-5381.2009.00171.x. Epub 2009 Apr 9. Review.

17.

Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study.

Coyne DW, Andress DL, Amdahl MJ, Ritz E, de Zeeuw D.

Nephrol Dial Transplant. 2013 Sep;28(9):2260-8. doi: 10.1093/ndt/gft227. Epub 2013 Jun 19.

18.

Cardiovascular disease in chronic kidney failure: the role of VDR activators.

Wu-Wong JR, Tian J, Nakane M, Ma J, Fey TA, Kroeger P, Fryer RM, Reinhart GA.

Curr Opin Investig Drugs. 2006 Mar;7(3):206-13. Review.

PMID:
16555680
19.

Vitamin D, vitamin D receptor and the importance of its activation in patients with chronic kidney disease.

Bover J, Egido J, Fernández-Giráldez E, Praga M, Solozábal-Campos C, Torregrosa JV, Martínez-Castelao A.

Nefrologia. 2015;35(1):28-41. doi: 10.3265/Nefrologia.pre2014.Sep.11796. English, Spanish.

20.

[Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].

Cases Amenós A, Goicoechea Diezhandiño M, de Alvaro Moreno F.

Nefrologia. 2008;28 Suppl 3:39-48. Spanish.

PMID:
19018737
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk